ClinicalTrials.gg
CompletedNCT02228681Updated Sep 19, 2024Results posted

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

A Phase 2 interventional study of Everolimus and Tamoxifen in Advanced, Persistent, or Recurrent Endometrial Cancer, sponsored by GOG Foundation. Completed at 26 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by GOG Foundation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letrozole in Endometrial Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. Letrozole · Endometrial Neoplasms.

Enrollment
7th of 17
74 · median 53
Started
2015
the only one that year
Phase 2
12 of 17
2 open now
Registered
7th of 17
by date
Lead sponsor
1 of 17
GOG Foundation

Among the 17 studies testing letrozole in Endometrial Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 2, and was the 7th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

5 of the 17 studies testing letrozole in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letrozole in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

03

Conditions studied

  • Advanced, Persistent, or Recurrent Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed advanced (FIGO Stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy. Histologic documentation of the recurrence is not required.
  • All patients must have . Measurable disease is defined by version 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be greater than or equal to 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray. Lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI (See section 8).
  • Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST 1.1 (Section 8.1). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a is obtained to confirm persistence at least 90 days following completion of radiation therapy.
  • Prior chemoradiotherapy for a pelvic recurrence is permitted. Prior chemotherapy in the setting for Stage I, II or III disease is permitted.

Note: No prior chemotherapy in the setting of Stage IV disease is permitted unless the patient was without evidence of disease at the completion of chemotherapy and had at least six months of progression-free survival since the completion of chemotherapy.

Regardless of circumstances, no more than one prior chemotherapy regimen (including chemo-radiotherapy) is permitted.

  • Patient must be able to take p.o. medications.
  • Performance status must be 0-1.
  • Patients must have adequate organ and marrow function as defined below:

NOTE: Institutional/laboratory = ULN Institutional/laboratory lower limit of normal = LLN

  • Bone marrow function:

    • (ANC) greater than or equal to 1,500/mcl
    • greater than or equal to 100,000 cells/mcl
    • greater than or equal to 9 g/dL
  • Coagulation

    • less than or equal to 1.5 x ULN (or in range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin).
  • Renal function:

    • Creatinine less than or equal to 1.5 x ULN
  • Hepatic function:

    • less than or equal to 1.5 x ULN
    • and AST less than or equal to 3 x ULN
    • Alkaline phosphatase less than or equal to 2.5 x ULN
    • Albumin greater than or equal to 2.8 g/dL
  • Lipid panel:

    • Fasting serum cholesterol less than or equal to 300 mg/dL
    • Fasting triglycerides less than or equal to 300 mg/
  • At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: hysterectomy, resection of a lung nodule; minor: central venous access catheter placement).
  • At least 4 weeks must have elapsed since the patient received any radiation therapy.
  • Patients who have met the pre-entry requirements specified in Section 7.0
  • Patients must have signed an approved and authorization permitting release of personal health information.
  • All patients must be at least 18 years of age
  • Patients of must have a negative serum pregnancy test prior to the study entry and be practicing a highly effective form of .

During the study treatment and for 8 weeks after stopping the treatment. Highly effective contraception methods include combination of any two of the following:

  • Use of oral, injected or implanted hormonal methods of contraception or;
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS);
  • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
  • Total abstinence or;
  • Male/female sterilization. Women are considered and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received everolimus, any another mTOR inhibitor or any agent targeting the PI3K/AKT/mTOR pathway.
  • Known intolerance or to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
  • Patients who have previously received hormonal therapy for endometrial cancer.
  • Patients with concomitant invasive or a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the past five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol.
  • Patients receiving chronic treatment with systemic or another agent.
  • Patients with active or uncontrolled systemic infection.
  • Uncontrolled diabetes mellitus as defined by >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and anti-diabetic treatment must be monitored closely throughout the trial and adjusted as necessary.
  • Known severely impaired lung function, including:

    • grade 2 (or greater) hypoxia (decreased oxygen saturation with exercise [e.g., pulse oximeter \<88%]; intermittent supplemental oxygen)
  • Patients with a known history of cardiac disease. This includes:
  • Uncontrolled hypertension, defined as systolic greater than 150 mm Hg or diastolic greater than 90 mm Hg despite antihypertensive medications.
  • Myocardial infarction or unstable angina within 6 months prior to registration.
  • (NYHA) Class II or greater congestive heart failure.
  • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication. This does not include asymptomatic atrial fibrillation with controlled ventricular rate.
  • Cerebrovascular accident (CVA, stroke), (TIA) within 6 months prior to the first date of study therapy.
  • Patients who are pregnant or breast-feeding.
  • Patients with known central nervous system .
  • Patients with known (HIV) infection.
  • Patients with an impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease; uncontrolled nausea, vomiting and/or diarrhea; malabsorption syndrome; clinical signs and symptoms of gastrointestinal obstruction; and/or patients who require parenteral hydration and/or nutrition).
  • Patients who plan to receive within 1 week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.
  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder or coagulopathy.
  • Patients who are currently part of or have participated in any clinical investigation with an drug within 30 days prior to dosing.
  • Patients must be able to follow concomitant medication restrictions:

    • Avoid the use of strong /PgP inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole).
    • Use caution when co-administered with moderate CYP3A4/PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem).
    • Grapefruit, grapefruit juice, and other foods known to inhibit cytochrome P450 and PgP activity may increase everolimus exposures and should be avoided during treatment.
    • Avoid the use of concomitant strong CYP3A4/PgP inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, and phenobarbital).
    • St. John's Wort may decrease everolimus exposure unpredictably and should be avoided.
  • Patients with active or C. Screening for hepatitis B

Prior to randomization/start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBsAg, HBcAb, HBsAb and quantitative hepatitis B DNA PCR (HBV-DNA):

  • All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece.

[http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm]

  • Patients with any of the following risk factors:
  • known or suspected past hepatitis B infection,
  • blood transfusion(s) prior to 1990,
  • current or prior IV drug users,
  • current or prior dialysis,
  • household contact with hepatitis B infected patient(s),
  • current or prior high-risk sexual activity,
  • body piercing or tattoos,
  • mother known to have hepatitis B
  • history suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain.
  • Additional patients at the discretion of the investigator The management guidelines, in Section 6, are provided according to the results of the baseline assessment of viral load and serological markers for hepatitis B.

Screening for

Patients with any of the following risk factors for hepatitis C should be tested using quantitative RNA-PCR:

  • known or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment),
  • blood transfusions prior to 1990,
  • current or prior IV drug users,
  • current or prior dialysis,
  • household contact of hepatitis C infected patient(s),
  • current or prior high-risk sexual activity,
  • body piercing or tattoos. At the discretion of the investigator, additional patients may also be tested for hepatitis C.

The management guidelines, in Section 6 are provided according to the results of the baseline assessment of hepatitis C viral load.

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Everolimus and Letrozole

    Everolimus 10 mg daily and Letrozole 2.5 mg PO daily

    Drug: Everolimus · Drug: Letrozole

  • Active comparator
    Hormonal Therapy

    Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID

    Drug: Tamoxifen · Drug: Medroxyprogesterone Acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of Response

    A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: From date of randomization until the date of first documented progression or date of death , up to 3 years.

Secondary outcomes

  1. Median Progression-free Survival

    Progression-free Survival is defined as the duration alive from study entry until progression is documented, or death; whichever comes sooner. Progressive disease is defined as at least a 5 mm absolute increase and a 20% relative increase in the sum of measurable target lesions' longest dimensions relative to the smallest sum at baseline or on study or the appearance of new lesions or unequivocal progression of existing non-target lesions.

    Time frame: Tumor measurements were done at 8 and 16 weeks after initiating treatment and then every 12 weeks and compared with baseline measurements prior to treatment. Measurements are continued until disease progression is documented or death.

  2. Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4

    Maximum grade of physician assessed adverse events graded and categorized using Common Toxicity Criteria for Adverse Events (CTCAE) version 4

    Time frame: Assessed throughout the treatment period and for 30 days after discontinuation of treatment. Treatment continues until progression of disease.

  3. Median Survival

    Survival is defined as the duration alive from study entry until death.

    Time frame: Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.

Other outcomes

  1. Hormone Receptor Immunohistochemistry

    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for hormone receptor (estrogen receptor-alpha, estrogen receptor-beta, progesterone receptor-A, progesterone receptor B and the G protein-coupled estrogen receptor, GPR-30) immunohistochemistry.

    Time frame: At study entry

  2. mTOR Pathway Immunohistochemistry

    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for mTOR pathway (including phosphorylated S6 ribosomal protein, PTEN, total and phosphorylated AKT, total and phosphorylated mTOR, and phospho-ERK1/2) immunohistochemistry

    Time frame: At study entry

  3. Mutation Analysis

    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue and DNA extracted from whole blood will be used for mutational analysis (including PTEN, PIK3CA, KRAS, and CTNNB1 (beta-catenin) performed using a sequencing panel assay.

    Time frame: At study entry

07

Results

Posted May 24, 2019

Participant flow

The study was activated on 02/19/2015 and closed to accrual on 04/18/2016. All patients underwent disease evaluation and were found to have measurable histologically confirmed advanced stage, persistent or recurrent endometrial carcinoma. After obtaining informed consent and verification of eligibility, patients were enrolled and treated.

Participant flow — Overall Study
MilestoneEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Started3737
Completed3737
Not completed00

Outcome measures

PrimaryFrequency of Response

A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
From date of randomization until the date of first documented progression or date of death , up to 3 years.
Reported as:
Number · Number of participants
Frequency of Response
Number of participantsEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Frequency of Response98
SecondaryMedian Progression-free Survival

Progression-free Survival is defined as the duration alive from study entry until progression is documented, or death; whichever comes sooner. Progressive disease is defined as at least a 5 mm absolute increase and a 20% relative increase in the sum of measurable target lesions' longest dimensions relative to the smallest sum at baseline or on study or the appearance of new lesions or unequivocal progression of existing non-target lesions.

Time frame:
Tumor measurements were done at 8 and 16 weeks after initiating treatment and then every 12 weeks and compared with baseline measurements prior to treatment. Measurements are continued until disease progression is documented or death.
Reported as:
Median · months
Median Progression-free Survival
monthsEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Median Progression-free Survival6.4 (3.8 to 17.7)3.7 (2.5 to 8.9)
SecondaryFrequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4

Maximum grade of physician assessed adverse events graded and categorized using Common Toxicity Criteria for Adverse Events (CTCAE) version 4

Time frame:
Assessed throughout the treatment period and for 30 days after discontinuation of treatment. Treatment continues until progression of disease.
Reported as:
Count of participants · Participants
Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4
ParticipantsEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Grade 122
Grade 2614
Grade 32717
Grade 422
Grade 501
SecondaryMedian Survival

Survival is defined as the duration alive from study entry until death.

Time frame:
Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.
Reported as:
Median · Months
Median Survival
MonthsEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Median SurvivalNA (14.2 to NA)16.6 (7.6 to NA)
Other pre-specifiedHormone Receptor Immunohistochemistry

To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for hormone receptor (estrogen receptor-alpha, estrogen receptor-beta, progesterone receptor-A, progesterone receptor B and the G protein-coupled estrogen receptor, GPR-30) immunohistochemistry.

Time frame:
At study entry

Results for this outcome have not been posted.

Other pre-specifiedmTOR Pathway Immunohistochemistry

To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for mTOR pathway (including phosphorylated S6 ribosomal protein, PTEN, total and phosphorylated AKT, total and phosphorylated mTOR, and phospho-ERK1/2) immunohistochemistry

Time frame:
At study entry

Results for this outcome have not been posted.

Other pre-specifiedMutation Analysis

To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue and DNA extracted from whole blood will be used for mutational analysis (including PTEN, PIK3CA, KRAS, and CTNNB1 (beta-catenin) performed using a sequencing panel assay.

Time frame:
At study entry

Results for this outcome have not been posted.

Adverse events

Collected over up to 30 days after the last cycle.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus and Letrozole13/37 (35.1%)13/37 (35.1%)37/37 (100%)
Tamoxifen and Medroxyprogesterone Acetate20/36 (55.6%)10/36 (27.8%)36/36 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
Thromboembolic EventVascular disorders0/373/36
Lung InfectionInfections and infestations3/371/36
Urinary Tract InfectionInfections and infestations2/370/36
AnemiaBlood and lymphatic system disorders0/371/36
Supraventricular TachycardiaCardiac disorders0/371/36
AscitesGastrointestinal disorders0/371/36
IleusGastrointestinal disorders0/371/36
CholecystitisHepatobiliary disorders0/371/36
SepsisInfections and infestations1/371/36
Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/371/36
Most frequent other events
Showing 10 of 196
Most frequent other events
EventEverolimus and LetrozoleTamoxifen and Medroxyprogesterone Acetate
AnemiaBlood and lymphatic system disorders25/3720/36
Mucositis OralGastrointestinal disorders24/374/36
HyperglycemiaMetabolism and nutrition disorders23/3711/36
FatigueGeneral disorders22/3715/36
HypertriglyceridemiaMetabolism and nutrition disorders20/378/36
NauseaGastrointestinal disorders19/3712/36
DiarrheaGastrointestinal disorders18/377/36
CoughRespiratory, thoracic and mediastinal disorders18/377/36
White Blood Cell DecreasedInvestigations17/374/36
Cholesterol HighInvestigations16/373/36

Baseline characteristics

Eligible and evaluable patients

Age, Continuous
Age, Continuous(years)Everolimus and LetrozoleTamoxifen and Medroxyprogesterone AcetateTotal
Mean63.3 ± 9.166.8 ± 7.365 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus and LetrozoleTamoxifen and Medroxyprogesterone AcetateTotal
Female373774
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Everolimus and LetrozoleTamoxifen and Medroxyprogesterone AcetateTotal
Hispanic or Latino448
Not Hispanic or Latino333366
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Everolimus and LetrozoleTamoxifen and Medroxyprogesterone AcetateTotal
American Indian or Alaska Native213
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American257
White323163
More than one race000
Unknown or Not Reported000
08

Study locations

26 sites
  • University of Colorado - Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Miami - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
  • Maine Medical Center
    Scarborough, Maine 04074, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • University of Massachusetts Memorial Center
    Worcester, Massachusetts 01605, United States
  • Sanford Clinic North - Bemidji
    Bemidji, Minnesota 56601, United States
  • St. Dominic-Jackson Memorial Hospital
    Jackson, Mississippi 39215, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Women's Cancer Center of Nevada
    Las Vegas, Nevada 89169, United States
  • New Mexico Cancer Alliance
    Albuquerque, New Mexico 87106, United States
  • Memorial Medical Center-Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Women's Cancer Care Associates
    Albany, New York 12208, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Sanford Roger Maris Cancer Center
    Fargo, North Dakota 58122, United States
  • University Hospital Case Medical Center
    Cleveland, Ohio 44106, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001-3788, United States
  • The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Magee Women's Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
  • Sanford Medical Center - Sioux Falls
    Sioux Falls, South Dakota 57104, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jan 2018, 32 months.

Results were first posted in May 2019, 1 year 4 months after primary completion.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's 32 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 29, 2014
StartActual
May 21, 2015
Primary completionActual
Jan 2018
CompletionActual
Aug 22, 2024
Results first posted
May 24, 2019
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02228681
Lead sponsor
GOG Foundation
Responsible party
Sponsor
First posted
Aug 29, 2014
Start date
May 21, 2015
Primary completion
Jan 2018
Completion
Aug 22, 2024
Results posted
May 24, 2019
Last update
Sep 19, 2024

Study contacts

Brian Slomovitz, MD
study chair · Gynecologic Oncology Group

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Letrozole

Start the discussion